Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Thérapeutique des Affections Inflammatoires Digestives - PubMed
Clinical Trial
Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Thérapeutique des Affections Inflammatoires Digestives
R Modigliani et al. Gastroenterology. 1990 Apr.
Abstract
One hundred forty-two patients with active colonic or ileocolonic Crohn's disease were included in a multicenter prospective study. Data collection included 28 clinical, biological, and endoscopic items; the latter were recorded according to a standardized colonoscopic protocol; a previously validated endoscopic index of severity was calculated. Oral prednisolone (1 mg/kg body wt per day) was started and maintained until clinical remission and for at least 3 and at most 7 wk. A second clinical biological and endoscopic evaluation was then performed. At initial colonoscopy, mucosal lesions were, by decreasing order of frequency, superficial ulcerations, deep ulcerations, mucosal edema, erythema, pseudopolyps, aphthoid ulcers, ulcerated stenosis, and nonulcerated stenosis (93%, 74%, 48%, 44%, 41%, 35%, 10%, 8%, and 2% of cases, respectively). No correlation was found between the clinical activity index and any of the endoscopical data (lesion frequency and surface, endoscopic severity index). Ninety-two percent of patients underwent clinical remission within 7 wk of treatment. None of the 28 clinical biological and endoscopical items collected just before treatment could predict clinical response to steroids. Only 38 of the 131 patients in clinical remission were also in endoscopic remission. In conclusion, (a) the description and severity of colonoscopic lesions in active Crohn's disease have been quantified; (b) no correlation exists between clinical severity and nature, surface, or severity of endoscopic lesions; (c) Oral prednisolone (1 mg/kg body wt per day) induces a clinical remission in 92% of patients within 7 wk; (d) resistance to steroids cannot be predicted from the data collected before treatment onset; and (e) only 29% of patients in clinical remission also achieve endoscopic remission.
Similar articles
-
Landi B, Anh TN, Cortot A, Soule JC, Rene E, Gendre JP, Bories P, See A, Metman EH, Florent C, et al. Landi B, et al. Gastroenterology. 1992 May;102(5):1647-53. doi: 10.1016/0016-5085(92)91725-j. Gastroenterology. 1992. PMID: 1568574 Clinical Trial.
-
Cellier C, Sahmoud T, Froguel E, Adenis A, Belaiche J, Bretagne JF, Florent C, Bouvry M, Mary JY, Modigliani R. Cellier C, et al. Gut. 1994 Feb;35(2):231-5. doi: 10.1136/gut.35.2.231. Gut. 1994. PMID: 7508411 Free PMC article.
-
Low dose naltrexone for induction of remission in Crohn's disease.
Segal D, Macdonald JK, Chande N. Segal D, et al. Cochrane Database Syst Rev. 2014 Feb 21;(2):CD010410. doi: 10.1002/14651858.CD010410.pub2. Cochrane Database Syst Rev. 2014. PMID: 24558033 Updated. Review.
-
Colonoscopic findings in Crohn's disease--reproducible, but of questionable benefit.
Holloway H, Fielding JF. Holloway H, et al. Can J Gastroenterol. 1996 Oct;10(6):405-12. doi: 10.1155/1996/353967. Can J Gastroenterol. 1996. PMID: 9193778 Review.
Cited by
-
Zubin G, Peter L. Zubin G, et al. Inflamm Bowel Dis. 2015 Jun;21(6):1386-91. doi: 10.1097/MIB.0000000000000388. Inflamm Bowel Dis. 2015. PMID: 25851564 Free PMC article.
-
Roseira J, Ventosa AR, de Sousa HT, Brito J. Roseira J, et al. United European Gastroenterol J. 2020 Dec;8(10):1208-1216. doi: 10.1177/2050640620943089. Epub 2020 Jul 14. United European Gastroenterol J. 2020. PMID: 32664824 Free PMC article.
-
Calprotectin as a diagnostic tool for inflammatory bowel diseases.
Chatzikonstantinou M, Konstantopoulos P, Stergiopoulos S, Kontzoglou K, Verikokos C, Perrea D, Dimitroulis D. Chatzikonstantinou M, et al. Biomed Rep. 2016 Oct;5(4):403-407. doi: 10.3892/br.2016.751. Epub 2016 Sep 7. Biomed Rep. 2016. PMID: 27699005 Free PMC article.
-
Risk-benefit assessment of drugs used in the treatment of inflammatory bowel disease.
Hanauer SB, Stathopoulos G. Hanauer SB, et al. Drug Saf. 1991 May-Jun;6(3):192-219. doi: 10.2165/00002018-199106030-00005. Drug Saf. 1991. PMID: 1676590 Review.
-
Standards of medical treatment and nutrition in Crohn's disease.
Siegmund B, Zeitz M. Siegmund B, et al. Langenbecks Arch Surg. 2005 Nov;390(6):503-9. doi: 10.1007/s00423-004-0498-3. Epub 2004 Sep 23. Langenbecks Arch Surg. 2005. PMID: 15449064 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical